Bioptik Technology (4161) - Total Assets
Based on the latest financial reports, Bioptik Technology (4161) holds total assets worth NT$1.57 Billion TWD (≈ $49.52 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Bioptik Technology cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Bioptik Technology - Total Assets Trend (2017–2025)
This chart illustrates how Bioptik Technology's total assets have evolved over time, based on quarterly financial data. Check 4161 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Bioptik Technology - Asset Composition Analysis
Current Asset Composition (December 2025)
Bioptik Technology's total assets of NT$1.57 Billion consist of 59.5% current assets and 40.5% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 25.4% |
| Accounts Receivable | NT$38.47 Million | 2.5% |
| Inventory | NT$203.18 Million | 12.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Bioptik Technology's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Bioptik Technology.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioptik Technology's current assets represent 59.5% of total assets in 2025, an increase from 59.2% in 2017.
- Cash Position: Cash and equivalents constituted 25.4% of total assets in 2025, down from 25.5% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 12.9% of total assets.
Bioptik Technology Competitors by Total Assets
Key competitors of Bioptik Technology based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Bioptik Technology - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.93 | 1.93 | 1.54 |
| Quick Ratio | 1.51 | 1.47 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$451.15 Million | NT$416.67 Million | NT$264.31 Million |
Bioptik Technology - Advanced Valuation Insights
This section examines the relationship between Bioptik Technology's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.7% |
| Total Assets | NT$1.57 Billion |
| Market Capitalization | $43.53 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bioptik Technology's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bioptik Technology's assets grew by 5.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bioptik Technology (2017–2025)
The table below shows the annual total assets of Bioptik Technology from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.57 Billion ≈ $49.52 Million |
+5.65% |
| 2024-12-31 | NT$1.49 Billion ≈ $46.87 Million |
-0.67% |
| 2023-12-31 | NT$1.50 Billion ≈ $47.19 Million |
-1.16% |
| 2022-12-31 | NT$1.52 Billion ≈ $47.74 Million |
-0.57% |
| 2021-12-31 | NT$1.52 Billion ≈ $48.01 Million |
+3.40% |
| 2020-12-31 | NT$1.47 Billion ≈ $46.43 Million |
-5.19% |
| 2019-12-31 | NT$1.55 Billion ≈ $48.97 Million |
-3.08% |
| 2018-12-31 | NT$1.60 Billion ≈ $50.53 Million |
+2.45% |
| 2017-12-31 | NT$1.57 Billion ≈ $49.32 Million |
-- |
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more